Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renoprotective Effects of Dapagliflozin vs Pentoxifylline in CKD
NCT06421870Phase 3Recruiting
- Sponsor
- Ain Shams University
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in chronic kidney disease (CKD) (3 arms), sponsored by Ain Shams University. Primary endpoints: Change in estimated glomerular filtration rate at 1 year and Change in proteinuria at 1 year. Started Mar 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06421870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421870.